OPEN ACCESS Freely available online

Molecular Pathology and Biochemistry

Commentary

Metabolic Reprogramming in Cancer Cells: Biochemical Perspectives

Fatima Noor*

Department of Clinical Pathology, University of Karachi, Karachi, Pakistan.

ABOVE THE STUDY

Metabolic reprogramming in cancer cells has emerged as one of the defining hallmarks of tumor biology, fundamentally reshaping how we understand cancer development and progression. In my opinion, this phenomenon is not merely a secondary adaptation to uncontrolled proliferation but a core driver of malignancy itself. Cancer cells actively remodel their biochemical pathways to meet the energetic, biosynthetic, and redox demands of rapid growth, survival under stress, and metastasis.

At the biochemical level, normal cells primarily rely on oxidative phosphorylation in mitochondria to generate efficiently. Cancer cells, however, frequently shift toward aerobic glycolysis, a phenomenon known as the Warburg effect. Even in the presence of oxygen, tumor cells preferentially convert glucose into lactate, producing less ATP per molecule of glucose but enabling faster energy production and providing intermediates for biosynthetic pathways. In my view, this metabolic shift reflects a strategic trade-off: efficiency is sacrificed for speed and flexibility, which are essential for uncontrolled proliferation.

Beyond glycolysis, cancer cells also rewire multiple interconnected metabolic pathways. Glutamine metabolism, or glutaminolysis, becomes a critical energy source and provides carbon and nitrogen for nucleotide and amino acid synthesis. Lipid metabolism is similarly altered, with increased fatty acid synthesis supporting membrane production and signaling molecule generation. These coordinated changes illustrate that metabolic reprogramming is not restricted to a single pathway but involves a global restructuring of cellular biochemistry.

A key driver of these metabolic changes is oncogenic signaling. Mutations in genes such as *MYC, RAS,* and PI3K/AKT/mTOR directly influence metabolic enzyme expression and activity. For example, *MYC* upregulates glycolytic enzymes and glutamine transporters, while PI3K/AKT signaling enhances glucose uptake and lipid synthesis. In my opinion, these oncogenes function not only as regulators of cell growth but also as master controllers of metabolic identity, linking signaling pathways directly to biochemical flux.

Hypoxia within the tumor microenvironment further intensifies metabolic reprogramming. As tumors grow, regions become oxygen-deprived, activating hypoxia-inducible factors (HIFs). These transcription factors shift cellular metabolism toward glycolysis while suppressing mitochondrial respiration. This adaptation allows cancer cells to survive in low-oxygen conditions but also promotes angiogenesis, invasion, and metastasis. The biochemical flexibility induced by hypoxia is therefore a key contributor to tumor aggressiveness.

Another important aspect of cancer metabolism is redox balance. Rapid proliferation generates high levels of Reactive Oxygen Species (ROS), which can damage cellular components. To counteract this, cancer cells enhance antioxidant systems such as glutathioneproduction. This redox adaptation not only protects tumor cells from oxidative damage but also supports signaling pathways that promote survival and growth. In my view, the ability of cancer cells to maintain redox homeostasis under stress is a critical but often underappreciated aspect of their metabolic resilience.

Metabolic reprogramming also influences epigenetic regulation. Many metabolites act as cofactors for enzymes that modify DNA and histones. For example, acetyl-CoA is required for histone acetylation, while α-ketoglutarate is involved in DNA demethylation processes. Altered levels of these metabolites in cancer cells can therefore reshape gene expression patterns, creating a feedback loop between metabolism and epigenetic control. This integration of biochemical and genetic regulation adds another layer of complexity to tumor biology.

Importantly, cancer metabolism is not uniform across all tumors or even within a single tumor. Intratumoral heterogeneity leads to metabolic specialization, where different cancer cell populations rely on distinct metabolic pathways. Some cells may depend heavily on glycolysis, while others utilize oxidative phosphorylation or fatty acid oxidation. This metabolic diversity contributes to treatment resistance, as targeting one pathway may not affect all tumor subpopulations.

From a therapeutic perspective, targeting cancer metabolism offers promising opportunities. Drugs that inhibit glycolysis,

Correspondence to Fatima Noor. Department of Clinical Pathology, University of Karachi, Karachi, Pakistan. E-mail: fatima.noor@uok.edu.pk

Received: 18-Aug-2025, Manuscript No. JMPB-25-41763; **Editor assigned:** 20-Aug-2025, PreQC No. JMPB-25-41763 (PQ); **Reviewed:** 03-Sep-2025, QC No. JMPB-25-41763; **Revised:** 10-Sep-2025, Manuscript No. JMPB-25-41763 (R); **Published:** 17-Sep-2025. DOI: 10.35248/jmpb.25.6.224.

Citation: Noor F (2025 Metabolic Reprogramming in Cancer Cells: Biochemical Perspectives. J Mol Pathol Biochem.6:224.

glutaminolysis, or lipid synthesis are being explored as potential anti-cancer agents. However, in my opinion, the challenge lies in the adaptability of cancer cells, which can often switch metabolic pathways in response to therapeutic pressure. This metabolic plasticity necessitates combination therapies and a deeper understanding of metabolic network dependencies.

In conclusion, metabolic reprogramming in cancer cells represents a fundamental biochemical adaptation that supports tumor growth, survival, and progression. In my view, it should be regarded not as a secondary feature of cancer but as a central hallmark of malignancy. A deeper biochemical understanding of these metabolic shifts will be essential for developing more effective, targeted, and durable cancer therapies in the future.